Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument
Executive Summary
Amgen, Biogen, Pfizer and Teva generated more than twice their global R&D budgets with higher pricing in the US compared to Western Europe and Canada, researchers at Memorial Sloan Kettering found.
You may also be interested in...
PhRMA Uses Allergan Stage In Campaign To Keep Focus On Industry's Reputation For Innovation
PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.
Drug Pricing ‘Solutions’ Coming In Future Phase Of US Healthcare Reform, Sec. Price Says
Trump tweets about plans for 'new system where there will be competition' to address Rx costs as Republican effort to repeal and replace the Affordable Care Act officially gets underway with release of two House bills.
Drug Pricing ‘Biggest Offenders’ Are Annual Increases On Widely Used Brands
Express Scripts Chief Medical Officer Steve Miller suggests that caps on annual price increases could significantly ease payer concerns over drug pricing.